# Study Assessing Pain Relief After Replacement of the Knee

> **NCT05260008** · PHASE2 · TERMINATED · sponsor: **Allay Therapeutics, Inc.** · enrollment: 112 (actual)

## Conditions studied

- Acute Postoperative Pain

## Interventions

- **DRUG:** ATX-101
- **DRUG:** ATX-101
- **DRUG:** bupivacaine hydrochloride without epinephrine

## Key facts

- **NCT ID:** NCT05260008
- **Lead sponsor:** Allay Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-07
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-01-15
- **Target enrollment:** 112 (ACTUAL)
- **Why stopped:** Based on positive data from the dose-ranging portion of the study, Sponsor decided as of May 28, 2024 not to move forward with the previously designed global ATX101-TKA-003 study.
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05260008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05260008, "Study Assessing Pain Relief After Replacement of the Knee". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05260008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*